Lasa Supergenerics Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Lasa Supergenerics Ltd is ₹ 7.96 as of 30 Apr 15:30 . The P/E Ratio of Lasa Supergenerics Ltd changed from 10.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Lasa Supergenerics Ltd changed from ₹ 243.63 crore on March 2021 to ₹ 84.42 crore on March 2025 . This represents a CAGR of -19.10% over 5 yearsThe Market Cap of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 14.94 crore on March 2025 to ₹ 14.94 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 2.22 crore as compare to the Sep '25 revenue of ₹ 3.07 crore. This represent the decline of -27.69% The revenue of Venmax Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1.62 crore as compare to the Sep '25 revenue of ₹ 1.32 crore. This represent the growth of 22.73% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ -0.73 crore as compare to the Sep '25 ebitda of ₹ -3.99 crore. This represent the decline of -81.7% The ebitda of Venmax Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.05 crore. This represent the decline of -20% The net profit of Lasa Supergenerics Ltd changed from ₹ -2.73 crore to ₹ -2.55 crore over 7 quarters. This represents a CAGR of -3.82% The net profit of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0.01 crore to ₹ 0.03 crore over 7 quarters. This represents a CAGR of 87.34% The Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

About Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998.
The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'.
Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc. The Company is developing the oncology products in R&D.

FAQs for the comparison of Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Lasa Supergenerics Ltd or Venmax Drugs & Pharmaceuticals Ltd?

Market cap of Lasa Supergenerics Ltd is 39 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 28 Cr

What are the key factors driving the stock performance of Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd?

The stock performance of Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd?

As of May 4, 2026, the Lasa Supergenerics Ltd stock price is INR ₹7.96. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹24.51.

How do dividend payouts of Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lasa Supergenerics Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.